Scintimammography with technetium-99m methoxyisobutylisonitrile: Results of a prospective European multicentre trial

European Journal of Nuclear Medicine

Volumn 25, Issue 4, 1998, Pages 375-385

  Palmedo, H ^a   Biersack, H J ^a   Lastoria, S ^b   Maublant, J ^c   Prats, E ^d   Stegner, H E ^e   Bourgeois, P ^f   Hustinx, R ^g   Hilson, A J W ^h   Bischof Delaloye, A ⁱ  

^a UNIVERSITY OF BONN   (Germany)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c CENTRE JEAN PERRIN   (France)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^e UNIVERSITY OF HAMBURG   (Germany)

^f SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY OF LIÈGE   (Belgium)

^h NATIONAL HEALTH SERVICE   (United Kingdom)

ⁱ UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Breast cancer; Dense breasts; Mammography; Scintimammography; Technetium 99m methoxyisobutylisonitrile

Indexed keywords

TECHNETIUM 99M;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EUROPE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE QUALITY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MULTICENTER STUDY; SCINTISCANNING; TIME; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI;

EID: 0343866908     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050235     Document Type: Article

References (55)

1. Kelsey JL, Gammon MD. The epidemiology of breast cancer. Cancer 1991;41:146-165.
2. Berg JW, Hutter RV. Breast cancer. Cancer 1995;75:257-269.
3. Sondik EJ. Breast cancer trends. Incidence, mortality and survival. Cancer 1994;74:995-999.
4. Andersson I. Mammographic screening and mortality from breast cancer: Malmö mammographic screening trial. Brit J Med 1988;297:943-948.
5. Frisell J, Eklund G, Hellström L. et al. Randomized study of mammography screening - preliminary report on mortality in the Stockholm trial. Breast cancer research and treatment 1991;18:49-56.
6. Miller AB, Baines CJ, To T, et al. Canada national breast screening study. Can Med Assoc J 1992;147:1459-1476.
7. Lannin DR, Harris RP, Swanson FH, Edwards MS, Swanson MS, Pories WJ. Difficulties in diagnosis of carcinoma of the breast in patients less than fifty years of age. Surg Gynecol Obstet 1993;177:457-476.
8. Coveney EC, Geraghty JG, O'Laoide R, Hourihane JB, O'Higgins NJ. Reasons underlying negative mammography in patients with palpable breast cancer. Clin Radiol 1994;49: 123-125.
9. Smart CR, Myers MH, Gloeckler LA Implications from SEER data on breast cancer management. Cancer 1978;41:787-789.
10. Carter CL, Allen C, Henson DE. Relation of tumour size, lymph node status and survival in 2474 breast cancer patients. Cancer 1989;63:181-187.
11. Koscielny S, Tubiana M, Le MG, et al. Breast cancer. Relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer 1984;49: 709-715.
12. Fisher B, Redmond C, Fisher ER, et al. Ten-year result of randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312:674-681.
13. De Jager R, Abdel N, Serafini A,et al. Current status of cancer immunodetection with radiolabeled human monoclonal antibodies. Semin Nucl Med 1993;23:165-179.
14. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue F-18 fluoro-2-deoxy-D-glucose. Radiology 1991;179:765-770.
15. Tse NY, Hoh CK, Hawkins RH, Zinner MJ, Dahlbom M, Choi Y, Maddahi J, Brunicardi FC, Phelps ME, Glaspy JA. The application of positron emission tomographic imaging with FDG to the evaluation of breast disease. Ann Surg 1992;216:27-34.
16. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi GN, Tilbury RS. Positron emission tomography with FDG in the detection and staging of breast cancer. Cancer 1993;71:3920-3925.
17. Adler LP, Crowe JP, Al Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with F-18 deoxy-2-fluoro-D-glucose PET. Radiology 1993;187:743-750.
18. Avril N, Dose J, Jänicke F, et al. Metabolic characterization of breasts tumours with PET using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-1856.
19. Palmedo H, Bender H, Grünwald F et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Tc-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997;24: 1138-1145.
20. Scheidhauer K, Scharl A, Pietrzyk U, et al. Qualitative F-18 FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996;23: 618-623.
21. Crowe JP, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994;1:132-140.
22. Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 1994;21:432-436.
23. Khalkhali I, Mena I. Jouanne E, et al. Prone scintimammography in patients with suspicion of breast cancer. J Am Coll Surg 1994;178:491-497.
24. Khalkhali I, Cutrone JA, Mena I. Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 1995; 196:421-426.
25. Khalkhali I, Cutrone JA, Mena I, Diggles L, Venegas R, Vargas H, Jackson B, Klein S. Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med 1995;36:1784-1789.
26. Palmedo H. Grünwald F, Bender H, Schomburg A, Mallmann P, Krebs D, Biersack HJ. Scintimammography with Tc-99m MIBI: comparison with mammography and magnetic resonance imaging. Eur J Nucl Med 1996;23:940-946.
27. Palmedo H., Schomburg A, Gruenwald F, Mallmann P., Krebs D, Biersack HJ. Scintimammography with Tc-99m MIBI in suspicious breast lesions. J Nucl Med 1996;37:626-630.
28. Palmedo H, Schomburg A, Mallmann P, et al. (1996) Scintimammography with Tc-99m MIBI in patients with suspicion of primary breast cancer. Nucl Med Biol 1996;23:681-684.
29. 99mTc-MIBI prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 1995;36:1758-1765.
30. Villanueva-Meyer J, Leonhard MH, Briscoe E, et al. Mammoscintigraphy with Tc-99m sestamibi in suspected breast cancer. J Nucl Med 1996;37:926-930.
31. 99mTc-MIBI imaging versus dynamic MRI [abstract]. J Nucl Med 1995;35:51.
32. Burak Z, Argon M, Memis A, et al. Evaluation of palpable breast masses with Tc-99m MIBI: a comparative study with mammography and ultrasonography. Nucl Med Commun 1994;15:604-612.
33. Lee V, Sax EJ, McAneny DB, Pollack S, Blanchard RA, Beazley RM, Kavanah MT, Ward RJ. A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancer. J Nucl Med 1993;34:2095-2100.
34. Waxman AD, Ramanna L, Memsic LD, Foster CE, Silberman AW, Gleischmann SH, Brenner RJ, Brachman MB, Kuhar CJ, Yadegar J. Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 1993;34:18-23.
35. Cimitan M, Volpe R, Candiani E, et al. The use of Tl-201 in the preoperative detection of breast cancer: an adjunct to mammography and ultrasonography. Eur J Nucl Med 1995;22:1110-1117.
36. Mansi L, Rambaldi PF, Procaccini E, et al. Scintimammography with Tc-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases. Eur J Nucl Med 1996;23: 932-939.
37. Piccolo S, Lastoria S, Mainolfi C, Muto P, Bazzicalupo L, Salvatore M. Tc-99m MDP scintimammography to image primary breast cancer. J Nucl Med 1995;36:718-724.
38. Ell PJ. Keeping abreast of time. Eur J Nucl Med 1995;22: 967-969.
39. Sluyser M, Hoefnagel CA. Breast carcinomas detected by thallium-201 scintigraphy. Cancer Lett 1988;40:161-168.
40. Rijks LJ, Bakker PJ, van Tienhoven G, et al. Imaging of estrogen receptors in primary and metastatic breast cancer patients with 1-123 Z-MIVE. J Clin Oncol 1997;15:2536-2545.
41. Maublant JC, Zhang Z, Rapp M, Ollier M, Michelot J, Veyre A. In vitro uptake of technetium-99m teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m sestamibi and thallium-201. J Nucl Med 1993;34: 1949-1952.
42. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis 2-methoxyisobutylisonitrile technetium in cultured mouse fibroblasts. J Nucl Med 1990;31:1646-1653.
43. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Rex 1993;53:977-984.
44. Bender H, Friedrich E, Zamora PO, Guhlke S, Biersack HJ. Effect of Induction of multi-drug resistance on accumulation of Tc-99m sestamibi in vitro. Anticancer Res. 1997;17:1833-1840.
45. Ciarmiello A, Del Vecchio S, Potena MI, et al. Technetium99m-sestamibi efflux and P-glycoprotein expression in human breast carcinoma [abstract]. J Nucl Med 1995:36(Suppl.): 129P.
46. 99mTc-MIBI in cultured tumour cells decreases when multidrug resistance factor is over-expressed [abstract], J Nucl Med 1994;35(Suppl.):219P.
47. 99mTc-MIBI breast imaging in breast cancer detection [abstract]. J Nucl Med 1996;7:74P.
48. Kopans DB. The positive predictive value of mammography, AJR 1992;158:521-526.
49. Khalkhali I, Cutrone JA, Mena I, Diggles L, Khalkhali S, Venegas R, Klein S. The usefulness of scintimammography (SMM) in patients with dense breasts on mammogram [abstract]. J Nucl Med 1995;36:52.
50. 99mTc-MIBI breast imaging in the detection of breast cancer [abstract]. J Nucl Med 1996;37:74P.
51. Donnegan WL. Evaluation of a palpable breast mass. N Engl J Med 1992;327:937-942.
52. Simpson JF, Page DL. Prognostic value of histopathology in the breast. Semin Oncol 1992;19:254-262.
53. Waxman A. The role of Tc-99m MIBI in imaging breast cancers. Semin Nucl Med 1997;17:40-54.
54. Wagner RH, Karesh SM, Dillehay GL, Henkin RE. Accuracy of needle localization of scintigraphic abnormalities using a radio-directed biopsy system (RDBS) [abstract). J Nucl Med 1997;38:22P.
55. Khalkhali I, Mishkin FS, Diggles LE, Klein SR. Radionuclide-guided stereotactic prebiopsy localization of nonpalpable breast lesions with normal mammograms. J Nucl Med 1997;38:1019-1022.